Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 2.2x - 2.5x | 2.4x |
| Historical Pb Multiple | 2.1x - 2.9x | 2.4x |
| Fair Value | €195.69 - €216.29 | €205.99 |
| Upside | -14.9% - -6.0% | -10.4% |
| Benchmarks | - | Full Ticker |
| Quest Diagnostics Incorporated | - | NYSE:DGX |
| Cryo-Cell International, Inc. | - | NYSEAM:CCEL |
| Guardant Health, Inc. | - | NasdaqGS:GH |
| OPKO Health, Inc. | - | NasdaqGS:OPK |
| Precipio, Inc. | - | NasdaqCM:PRPO |
| Labcorp Holdings Inc. | - | DB:N6B |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| DGX | CCEL | GH | OPK | PRPO | N6B | |||
| NYSE:DGX | NYSEAM:CCEL | NasdaqGS:GH | NasdaqGS:OPK | NasdaqCM:PRPO | DB:N6B | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | 0.7% | -29.4% | NM- | NM- | NM- | -2.0% | ||
| 3Y CAGR | -24.2% | -42.2% | NM- | NM- | NM- | -30.2% | ||
| Latest Twelve Months | 13.0% | 98.2% | 15.7% | 27.1% | 53.0% | 69.8% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 12.9% | 0.0% | -95.1% | -15.1% | -90.5% | 9.6% | ||
| Prior Fiscal Year | 9.2% | -30.4% | -85.0% | -21.9% | -38.5% | 3.1% | ||
| Latest Fiscal Year | 8.8% | 1.3% | -59.0% | -7.5% | -23.1% | 5.7% | ||
| Latest Twelve Months | 9.0% | -0.5% | -49.9% | -26.7% | -15.5% | 5.7% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | 19.5% | 113.1% | -298.6% | -8.5% | -50.8% | 13.7% | ||
| Prior Fiscal Year | 13.9% | NM | -438.1% | -12.8% | -38.1% | 4.2% | ||
| Latest Twelve Months | 13.7% | NM | NM | -13.2% | -14.8% | 9.3% | ||
| Next Fiscal Year | 15.7% | -2.5% | 79.2% | -23.0% | 87.8% | 16.2% | ||
| Two Fiscal Years Forward | 15.5% | 1.9% | 33.3% | -32.1% | 67.5% | 15.9% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 1.9x | 1.1x | 8.8x | 1.6x | 1.1x | 1.7x | ||
| Price / LTM EPS | 21.6x | -205.5x | -17.7x | -6.1x | -12.9x | 29.4x | ||
| Price / Book | 2.8x | -2.3x | -23.9x | 0.8x | 1.9x | 2.7x | ||
| Price / Fwd Book | 2.8x | -1.9x | -16.1x | 1.0x | 0.7x | 2.5x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | -23.9x | 0.8x | 2.8x | |||||
| Historical P/B Ratio | 2.1x | 2.4x | 2.9x | |||||
| Selected P/B Multiple | 2.2x | 2.4x | 2.5x | |||||
| (x) Book Value | 8,473 | 8,473 | 8,473 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | DGX | CCEL | GH | OPK | PRPO | N6B | |
| Value of Common Equity | 20,445 | 35 | 7,304 | 1,080 | 23 | 22,237 | |
| (/) Shares Outstanding | 111.8 | 8.1 | 124.7 | 793.8 | 1.6 | 83.1 | |
| Implied Stock Price | 182.83 | 4.37 | 58.57 | 1.36 | 14.30 | 267.60 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.16 | |
| Implied Stock Price (Trading Cur) | 182.83 | 4.37 | 58.57 | 1.36 | 14.30 | 230.00 | |
| Trading Currency | USD | USD | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.16 | |